Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03342586 · ClinicalTrials.gov registry record
Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
A clinical trial of Central Nervous System Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 14
- Enrollment target
- 1
- Study location
NCT03342586: Completed study of Central Nervous System Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03342586 is a study of Central Nervous System Lymphoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 14 participants, below the 105-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03342586, a study of Central Nervous System Lymphoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test resting state functional Magnetic Resonance Imaging (rsfMRI) scans to see if rsfMRI scans are better than the standard task based fMRI scans at diagnosing or monitoring central nervous system lymphoma.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Resting State fMRI (rsfMRI)
- OTHER Auditory Attention and Executive Functions Test
- OTHER Memory Test
- OTHER Motor Speed Test
- OTHER Self Reported Quality of Life Questionnaire
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-11-07 |
| Est. Completion | 2022-08-04 |
What the finished NCT03342586 record still lists
NCT03342586 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 105-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Central Nervous System Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Resting State fMRI (rsfMRI) is the first listed.
NCT03342586 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03342586 about?
NCT03342586 is a clinical study titled "Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity". The purpose of this study is to test resting state functional Magnetic Resonance Imaging (rsfMRI) scans to see if rsfMRI scans are better than the standard task based fMRI scans at diagnosing or monitoring central nervous system lymphoma.
What is the current status of trial NCT03342586?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2017-11-07. Estimated completion is 2022-08-04.
What conditions does trial NCT03342586 study?
This clinical trial studies the following conditions: Central Nervous System Lymphoma.
What interventions are being tested in trial NCT03342586?
The interventions under investigation include: Resting State fMRI (rsfMRI) (DIAGNOSTIC_TEST), Auditory Attention and Executive Functions Test (OTHER), Memory Test (OTHER), Motor Speed Test (OTHER), Self Reported Quality of Life Questionnaire (OTHER).
Who is sponsoring clinical trial NCT03342586?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03342586 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03342586's enrollment target sits among peer trials
14 13th of 14 higher than 2 of 14 other Central Nervous System Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Central Nervous System Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
RECRUITING · Phase 1
-
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
RECRUITING · Phase 1
-
DALY II USA/ MB-CART2019.1 for DLBCL
RECRUITING · Phase 2
-
Long-term Follow-up Study of Patients Receiving CAR-T Cells
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy